GSA Capital Partners LLP Has $1.54 Million Stake in Arcus Biosciences, Inc. (NYSE:RCUS)

GSA Capital Partners LLP raised its stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 174.3% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 196,251 shares of the company's stock after buying an additional 124,701 shares during the quarter. GSA Capital Partners LLP owned approximately 0.19% of Arcus Biosciences worth $1,541,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Lazard Asset Management LLC lifted its stake in Arcus Biosciences by 3,321.3% in the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock valued at $93,000 after buying an additional 6,078 shares during the last quarter. PEAK6 LLC acquired a new position in shares of Arcus Biosciences during the fourth quarter valued at $149,000. KLP Kapitalforvaltning AS acquired a new position in shares of Arcus Biosciences during the fourth quarter valued at $207,000. Exchange Traded Concepts LLC increased its holdings in shares of Arcus Biosciences by 40.5% during the first quarter. Exchange Traded Concepts LLC now owns 13,922 shares of the company's stock valued at $109,000 after purchasing an additional 4,013 shares during the period. Finally, Brevan Howard Capital Management LP increased its holdings in shares of Arcus Biosciences by 38.3% during the fourth quarter. Brevan Howard Capital Management LP now owns 14,279 shares of the company's stock valued at $213,000 after purchasing an additional 3,957 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RCUS has been the topic of a number of research analyst reports. Wells Fargo & Company lowered their target price on Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Morgan Stanley lowered their target price on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Barclays lowered their target price on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. Wedbush reissued an "outperform" rating and issued a $33.00 price target on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group dropped their price target on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Arcus Biosciences presently has an average rating of "Moderate Buy" and a consensus target price of $21.29.

Arcus Biosciences Stock Up 0.3%

NYSE RCUS traded up $0.03 during trading on Friday, reaching $9.16. 805,025 shares of the company's stock were exchanged, compared to its average volume of 701,151. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $18.98. The firm has a market capitalization of $969.95 million, a PE ratio of -2.19 and a beta of 0.89. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.09. The company's fifty day simple moving average is $9.13 and its 200-day simple moving average is $9.63.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 70.58% and a negative net margin of 258.94%. The business had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. During the same quarter in the previous year, the business posted ($0.05) earnings per share. The company's revenue was down 80.7% compared to the same quarter last year. Sell-side analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.